SCHEMBL12935680

SCHEMBL12935680

Cc1cccnc1CN(Cc1ncccc1C)C1CCN(/C(N)=N/C#N)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 5/20 0.38
CCR5 P51681 5/20 0.36
KCNH2 Q12809 1/20 0.35
ALDH1A1 P00352 2/20 0.32
MAPT P10636 1/20 0.32
POLB P06746 1/20 0.32
EPHA2 P29317 1/20 0.32
EPHB4 P54760 1/20 0.32
CYP2D6 P10635 2/20 0.32
CHRM2 P08172 2/20 0.32
CHRM4 P08173 2/20 0.32
CHRM5 P08912 2/20 0.32
CHRM1 P11229 2/20 0.32
CHRM3 P20309 2/20 0.32
TDP1 Q9NUW8 1/20 0.32
PGR P06401 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP3A4 P08684 1/20 0.32
MEN1 O00255 1/20 0.32
MAPK1 P28482 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2082698 1.00 CXCR4 (0.38) CXCR4CCR5KCNH2ALDH1A1MAPT
SCHEMBL2082837 0.87 CXCR4 (0.40) CXCR4CCR5KCNH2ALDH1A1POLB
SCHEMBL12935384 0.87 CXCR4 (0.40) CXCR4CCR5KCNH2ALDH1A1POLB
SCHEMBL2084702 0.82 CXCR4 (0.41) CXCR4CCR5KCNH2ALDH1A1POLB
SCHEMBL12935360 0.82 CCR5 (0.41) CXCR4CCR5KCNH2ALDH1A1POLB
SCHEMBL12935469 0.81 CXCR4 (0.37) CXCR4CCR5KCNH2POLBCYP2D6
SCHEMBL2083632 0.81 CXCR4 (0.37) CXCR4CCR5KCNH2POLBCYP2D6
SCHEMBL2086381 0.79 CXCR4 (0.40) CXCR4CCR5CYP2D6CHRM2CHRM4
Hydroxyamine SCHEMBL4518793 0.79 CCR5 (0.43) CXCR4CCR5KCNH2POLBTDP1
SCHEMBL2082693 0.79 CXCR4 (0.36) CXCR4CCR5KCNH2CYP2D6CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7863293-B2 CXCR4 chemokine receptor binding compounds GENZYME CORPORATION (US) 2011-01-04 US disclosed
US-7863293-B2 CXCR4 chemokine receptor binding compounds GENZYME CORPORATION (US) 2011-01-04 US disclosed
US-20080255197-A1 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED CORPORATION (CA) 2008-10-16 US disclosed
US-20080255197-A1 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED CORPORATION (CA) 2008-10-16 US disclosed
US-7291631-B2 CXCR4 chemokine receptor binding compounds GENZYME CORPORATION (US) 2007-11-06 US disclosed
US-7291631-B2 CXCR4 chemokine receptor binding compounds GENZYME CORPORATION (US) 2007-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255197-A1 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS CXCR4, CXCR1, CXCR3 CXCR4 1/4885CCR5 4/4885KCNH2 3729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.